Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678938 | 1.00 | FLT1 (0.46) | FLT1FLT4KDRSMN1; SMN2TSHR | |
| SCHEMBL10580560 | 0.81 | TSHR (0.59) | FLT1FLT4KDRSMN1; SMN2TSHR | |
| SCHEMBL120474 | 0.79 | CYP11B2 (0.44) | SMN1; SMN2TSHRCASP1TMPRSS4GPR27 | |
| SCHEMBL1345954 | 0.79 | CES1 (0.44) | SMN1; SMN2IDO1MAPTNPC1RAB9A | |
| SCHEMBL20360438 | 0.78 | FLT1 (0.44) | FLT1FLT4KDRSMN1; SMN2TMPRSS4 | |
| SCHEMBL20360448 | 0.78 | FLT1 (0.41) | FLT1FLT4KDRSMN1; SMN2TSHR | |
| SCHEMBL20360446 | 0.78 | FLT1 (0.41) | FLT1FLT4KDRSMN1; SMN2TSHR | |
| SCHEMBL14310501 | 0.78 | FLT1 (0.46) | FLT1FLT4KDRSMN1; SMN2TSHR | |
| SCHEMBL20308955 | 0.78 | HTT (0.39) | SMN1; SMN2IDO1ALDH1A1HPGDMAPT | |
| SCHEMBL18043682 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRCASP1TMPRSS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472313-B1 | Process for synthesizing trifluoroketones | GRAPHENE 3D LAB INC. (US) | 2019-11-12 | — | — | US | claimed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| EP-3486242-B1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| WO-2010065333-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7709493-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-2178536-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | Lexicon Pharmaceuticals, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TERSERA THERAPEUTICS LLC | 2009-11-19 | — | — | US | disclosed |
| EP-2091940-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7553840-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2009014972-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TERSERA THERAPEUTICS LLC | 2008-06-26 | — | — | US | disclosed |
| WO-2008073933-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TPH1, TPH2, PAH | FLT1 2030/4885FLT4 2402/4885KDR 2534/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FLT1 1199/4885FLT4 2717/4885KDR 1536/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FLT1 1199/4885FLT4 2717/4885KDR 1536/4885 |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, F2, F7 | FLT1 1430/4885FLT4 2137/4885KDR 2328/4885 |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TPH1, TPH2, MAOA | FLT1 2715/4885FLT4 2783/4885KDR 2816/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FLT1 1199/4885FLT4 2717/4885KDR 1536/4885 |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | F11, F2, F7 | FLT1 1349/4885FLT4 2175/4885KDR 2373/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | FLT1 4810/4885FLT4 4610/4885KDR 4778/4885 |
| US-10472313-B1 | Process for synthesizing trifluoroketones | FRK, PFKFB2, PFKFB1 | FLT1 537/4885FLT4 582/4885KDR 221/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FLT1 1199/4885FLT4 2717/4885KDR 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.